Prof Scott Tykodi speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.
He gives an overview of the FRACTION-RCC trial, which is a randomised, open-label phase II trial that assessed multiple different combinations of nivolumab with a second agent, including ipilimumab, for the treatment of heavily pre-treated patients with advanced renal cell carcinoma.
Prof Tykodi describes the results of this study, in which patients achieved a 15.2% overall response rate, after a median follow-up of 8.9 months.
He notes, however, that no patients achieved a complete response, and only 7 patients achieved a partial response.
Prof Tykodi outlines the main conclusions of this study, and the potential clinical implications of these findings.